Fig. 4

Kinetic changes in serum NEO, sCD25, and sCD8 in NSCLC patients undergoing therapy with anti-PD-1/PD-L1s (Fig. a and c) and correlation between tested molecules (Fig. b and d). Samples were collected at baseline and at the end of the 1st, 2nd, 3rd, and 4th cycles from patients dosed with ATEZO or PEMBRO. In total, 249 serum samples were determined for NEO & sCD25 comparison (Fig. a and b) and 252 serum samples for NEO & sCD8 (Fig. c and d). Data in Fig. a and c are presented as medians (markers) along with the interquartile ranges (whiskers). A similar pattern of changes was observed for NEO and sCD25 (Fig. a) and not for NEO and sCD8 (Fig. c). The results were confirmed by Spearman’s test: there was a significant positive correlation between NEO and sCD25 (Fig. b) and no correlation between NEO and sCD8 (Fig. d).